Scientia Investigacion Clinica S.C.
Chihuahua City, Mexico
6 recruiting
Showing 1–10 of 10 trials
Recruiting
Phase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Eli Lilly and Company1,431 enrolled258 locationsNCT07415044
Recruiting
Phase 2
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Bipolar Disorder
Eli Lilly and Company400 enrolled87 locationsNCT07286175
Recruiting
Phase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Urinary Incontinence, Stress
Eli Lilly and Company1,000 enrolled137 locationsNCT07202884
Recruiting
Phase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Ulcerative Colitis
Eli Lilly and Company252 enrolled147 locationsNCT07186101
Recruiting
Phase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Asthma
Eli Lilly and Company531 enrolled121 locationsNCT07219173
Recruiting
Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled266 locationsNCT07213804
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled189 locationsNCT06937086
Recruiting
Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled186 locationsNCT06937099
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb600 enrolled295 locationsNCT06926868
Recruiting
Phase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Depressive Disorder, Major
Eli Lilly and Company1,000 enrolled180 locationsNCT07412756